RxDoctor Payments Data

Eric Stewart, MD

Dermatology · Fayetteville, ARNPI 1801973870

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.9% of the total across 263 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 31.2% of the total.

$4,577in general payments, 2019–2025

Across 263 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$759
  • Lilly USA, LLC$636
  • Pfizer$314
  • Sanofi$289
  • Novartis$266
  • plus $885 from 13 others

What the payments were for

  • Food & beverage$4,29894%
  • Education$2796%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,577 in reported general payments places this provider in the 55th percentile of 75 dermatology providers in Arkansas.

See all dermatology providers in Arkansas

Medicare billing

Part B allowed, 2024
$650,588
Medicare patients
1,007
Services billed
9,669

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab26$184,397
Dupixent PenDupilumab32$119,610
OtezlaApremilast20$96,541
Ketoconazole146$2,034
Clobetasol Propionate29$1,879
ValacyclovirValacyclovir Hcl50$1,415
Tretinoin18$1,397
Mupirocin172$1,390
Gabapentin84$882
Finasteride79$868
Triamcinolone Acetonide101$847
Cephalexin26$620
Betamethasone Dipropionate15$607
Metronidazole11$552
Doxycycline Hyclate26$422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$76$96,54120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 75 dermatology providers in Arkansas.

Other dermatology in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →